Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""humanized"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 11890
Tytuł:
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Autorzy:
Cirillo A; Department of Radiological, Oncological and Pathological Sciences, Sapienza University, 00161, Rome, Italy.
Marinelli D; Department of Experimental Medicine, Sapienza University, 00161, Rome, Italy. .
Romeo U; Department of Oral Sciences and Maxillofacial Surgery, Sapienza University, 00161, Rome, Italy.
Messineo D; Department of Radiological, Oncological and Pathological Sciences, Sapienza University, 00161, Rome, Italy.
De Felice F; Department of Radiological, Oncological and Pathological Sciences, Sapienza University, 00161, Rome, Italy.
De Vincentiis M; Department of Sense Organs, Sapienza University, 00161, Rome, Italy.
Valentini V; Department of Oral Sciences and Maxillofacial Surgery, Sapienza University, 00161, Rome, Italy.
Mezi S; Department of Radiological, Oncological and Pathological Sciences, Sapienza University, 00161, Rome, Italy.
Valentini F; Department of Oral Sciences and Maxillofacial Surgery, Sapienza University, 00161, Rome, Italy.
Vivona L; Department of Radiological, Oncological and Pathological Sciences, Sapienza University, 00161, Rome, Italy.
Chiavassa A; Department of Radiological, Oncological and Pathological Sciences, Sapienza University, 00161, Rome, Italy.
Cerbelli B; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, 04100, Latina, Italy.
Santini D; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, 04100, Latina, Italy.
Bossi P; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121, Brescia, Italy.
Polimeni A; Department of Oral Sciences and Maxillofacial Surgery, Sapienza University, 00161, Rome, Italy.
Marchetti P; Istituto Dermopatico dell'Immacolata (IDI-IRCCS), 00167, Rome, Italy.
Botticelli A; Department of Radiological, Oncological and Pathological Sciences, Sapienza University, 00161, Rome, Italy.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Apr 08; Vol. 24 (1), pp. 430. Date of Electronic Publication: 2024 Apr 08.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents, Immunological*/adverse effects
Head and Neck Neoplasms*/drug therapy
Head and Neck Neoplasms*/chemically induced
Antibodies, Monoclonal, Humanized*
Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; B7-H1 Antigen ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China.
Autorzy:
Peng DM; Department of Breast Surgery, Liaoning Cancer Hospital & Institute, 44 Xiaoheyan Road, NO, Shenyang, 110042, P.R. China.
Li J; Department of Breast Surgery, Liaoning Cancer Hospital & Institute, 44 Xiaoheyan Road, NO, Shenyang, 110042, P.R. China.
Qiu JX; Department of Breast Surgery, Liaoning Cancer Hospital & Institute, 44 Xiaoheyan Road, NO, Shenyang, 110042, P.R. China.
Zhao L; Department of Breast Surgery, Liaoning Cancer Hospital & Institute, 44 Xiaoheyan Road, NO, Shenyang, 110042, P.R. China. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2024 Apr 06; Vol. 22 (1), pp. 88. Date of Electronic Publication: 2024 Apr 06.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Antibodies, Monoclonal, Humanized*
Humans ; Female ; Trastuzumab/therapeutic use ; Trastuzumab/adverse effects ; Neoadjuvant Therapy/adverse effects ; Retrospective Studies ; Ki-67 Antigen/metabolism ; Receptor, ErbB-2/metabolism ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
Autorzy:
Quénéhervé L; Department of Gastroenterology, University Hospital of Brest, Brest, France.
Trang-Poisson C; Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, Nantes, France.
Fantou A; Nantes Université, CHU Nantes, CRT2I, UMR Inserm 1064, Nantes, France.
Flamant M; Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, Nantes, France.
Durand T; Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), UMR Inserm 1235 TENS, Nantes, France.
Bouguen G; Université de Rennes, CHU Rennes, Institut NUMECAN (Nutrition Metabolism and Cancer), Hepato-Gastroenterologie, Inserm CIC1414, Rennes, France.
Bregeon J; Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), UMR Inserm 1235 TENS, Nantes, France.
Oullier T; Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), UMR Inserm 1235 TENS, Nantes, France.
Amil M; CHD La Roche-Sur-Yon, Hepato-gastroentérologie, La Roche-Sur-Yon, France.
Dewitte M; Université de Rennes, CHU Rennes, Institut NUMECAN (Nutrition Metabolism and Cancer), Hepato-Gastroenterologie, Inserm CIC1414, Rennes, France.
Bardot S; Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, Nantes, France.
Blandin S; Nantes Université, UMS BioCore, Inserm US16-UAR CNRS 3556, Nantes, France.
Braudeau C; Nantes Université, CHU Nantes, CRT2I, UMR Inserm 1064, Nantes, France.
Vibet MA; CHU Nantes, Methodology and Biostatistics Department, Direction de la Recherche Clinique et de l'Innovation, Nantes, France.
Josien R; Nantes Université, CHU Nantes, CRT2I, UMR Inserm 1064, Nantes, France.
Neunlist M; Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), UMR Inserm 1235 TENS, Nantes, France.
Bourreille A; Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, Nantes, France.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Apr 02; Vol. 19 (4), pp. e0298313. Date of Electronic Publication: 2024 Apr 02 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Colitis, Ulcerative*
Antibodies, Monoclonal, Humanized*
Humans ; Pilot Projects ; Fluorescein-5-isothiocyanate ; Biomarkers ; Endoscopy, Gastrointestinal ; Gastrointestinal Agents/therapeutic use ; Treatment Outcome ; Remission Induction
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population.
Autorzy:
Weng CC; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei City, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Chi SC; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei City, Taiwan.
Lin TC; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei City, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Huang YM; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei City, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Chou YB; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei City, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Hwang DK; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei City, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Chen SJ; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei City, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Apr 02; Vol. 19 (4), pp. e0301096. Date of Electronic Publication: 2024 Apr 02 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Retinal Detachment*/etiology
Macular Degeneration*/drug therapy
Macular Degeneration*/epidemiology
Macular Degeneration*/complications
Wet Macular Degeneration*/drug therapy
Wet Macular Degeneration*/complications
Antibodies, Monoclonal, Humanized*
Humans ; Aged ; Aged, 80 and over ; Treatment Outcome ; Follow-Up Studies ; Retrospective Studies ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Tomography, Optical Coherence ; Visual Acuity ; Intravitreal Injections ; Vision Disorders/complications ; China ; Angiogenesis Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice.
Autorzy:
Frade-Sosa B; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Salman-Monte TC; Rheumatology Department, Hospital Del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain.
Narváez J; Rheumatology Department, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Peralta I; Rheumatology Department, Hospital Universitario Germans Trias I Pujol, Badalona, Spain.
Sandoval S; Rheumatology Department, Hospital Vall D'Hebron, Barcelona, Spain.
Magallares B; Rheumatology Department, Hospital Santa Creu I Sant Pau, Barcelona, Spain.
Heredia S; Rheumatology Department, Hospital Moisès Broggi, Barcelona, Spain.
Sapena N; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Riveros-Frutos A; Rheumatology Department, Hospital Universitario Germans Trias I Pujol, Badalona, Spain.
Olivé A; Rheumatology Department, Hospital Universitario Germans Trias I Pujol, Badalona, Spain.
Corominas H; Rheumatology Department, Hospital Santa Creu I Sant Pau, Barcelona, Spain.
Cortés-Hernández J; Rheumatology Department, Hospital Vall D'Hebron, Barcelona, Spain.
Gómez-Puerta JA; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło:
Lupus [Lupus] 2024 Apr; Vol. 33 (5), pp. 481-489. Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article
MeSH Terms:
Immunosuppressive Agents*/therapeutic use
Lupus Erythematosus, Systemic*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Treatment Outcome ; Personal Satisfaction
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review.
Autorzy:
Fan Q; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ji H; Department of Dermatology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu Y; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jia C; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zou L; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yang H; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pokaż więcej
Źródło:
Lupus [Lupus] 2024 Apr; Vol. 33 (4), pp. 414-419. Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Lupus Erythematosus, Systemic*/complications
Lupus Erythematosus, Systemic*/drug therapy
Hepatitis*/drug therapy
Recombinant Fusion Proteins*
Antibodies, Monoclonal, Humanized*
Humans ; Prospective Studies ; Treatment Outcome ; Immunosuppressive Agents/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
Autorzy:
Høilund-Carlsen PF; Department of Nuclear Medicine, Odense University Hospital, 5000 Odense C, Denmark.; Research Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical Research, University of Southern Denmark, 5230 Odense M, Denmark.
Alavi A; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Castellani RJ; Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Neve RL; Gene Delivery Technology Core, Massachusetts General Hospital, Boston, MA 02114, USA.
Perry G; Department of Neuroscience, Developmental and Regenerative Biology and Genetics of Neurodegeneration, University of Texas at San Antonio, San Antonio, TX 78249, USA.
Revheim ME; The Intervention Centre, Division of Technology and Innovation, Oslo University Hospital, 0372 Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, 0313 Oslo, Norway.
Barrio JR; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, LA 90095, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Mar 31; Vol. 25 (7). Date of Electronic Publication: 2024 Mar 31.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Alzheimer Disease*/therapy
Antibodies, Monoclonal, Humanized*
United States ; Humans ; Ice Cover ; Amyloidogenic Proteins ; Radioimmunotherapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.
Autorzy:
Hou C; Department of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, 107# Huanhu East Road, Shushan District, 230031, Hefei, Anhui, People's Republic of China. .; Graduate School of Bengbu Medical College, Bengbu, Anhui, China. .
Xiong B; Department of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, 107# Huanhu East Road, Shushan District, 230031, Hefei, Anhui, People's Republic of China.; Graduate School of Bengbu Medical College, Bengbu, Anhui, China.
Zhou L; Department of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, 107# Huanhu East Road, Shushan District, 230031, Hefei, Anhui, People's Republic of China.
Fei Y; Department of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, 107# Huanhu East Road, Shushan District, 230031, Hefei, Anhui, People's Republic of China.
Shi C; Department of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, 107# Huanhu East Road, Shushan District, 230031, Hefei, Anhui, People's Republic of China.
Zhu X; Department of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, 107# Huanhu East Road, Shushan District, 230031, Hefei, Anhui, People's Republic of China.
Xie T; Department of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, 107# Huanhu East Road, Shushan District, 230031, Hefei, Anhui, People's Republic of China.
Wu Y; Department of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, 107# Huanhu East Road, Shushan District, 230031, Hefei, Anhui, People's Republic of China.; Graduate School of Bengbu Medical College, Bengbu, Anhui, China.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Mar 27; Vol. 24 (1), pp. 387. Date of Electronic Publication: 2024 Mar 27.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Chemoembolization, Therapeutic*/adverse effects
Antibodies, Monoclonal, Humanized*
Humans ; Molecular Targeted Therapy ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).
Autorzy:
Streichart L; Transplant Institute, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 413 45, Gothenburg, Sweden.
Felldin M; Transplant Institute, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 413 45, Gothenburg, Sweden.
Ekberg J; Transplant Institute, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 413 45, Gothenburg, Sweden.
Mjörnstedt L; Transplant Institute, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 413 45, Gothenburg, Sweden.
Lindnér P; Transplant Institute, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 413 45, Gothenburg, Sweden.
Lennerling A; Transplant Institute, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 413 45, Gothenburg, Sweden.
Bröcker V; Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Mölne J; Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Holgersson J; Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg and Department of Clinical Immunology and Transfusion Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
Daenen K; Department of Nephrology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Wennberg L; Department of Transplantation Surgery, Karolinska University Hospital, Stockholm, Sweden.
Lorant T; Section of Transplantation Surgery, Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.
Baid-Agrawal S; Transplant Institute, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 413 45, Gothenburg, Sweden. .
Pokaż więcej
Źródło:
Trials [Trials] 2024 Mar 22; Vol. 25 (1), pp. 213. Date of Electronic Publication: 2024 Mar 22.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*/therapeutic use
Kidney Transplantation*/adverse effects
Humans ; Graft Rejection ; Kidney ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.
Autorzy:
Nannini S; Department of Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France.
Guisier F; Department of Pneumology, UNIROUEN, LITIS Lab QuantIF Team EA4108, CHU Rouen, Normandie University, Rouen and Inserm CIC-CRB 1404, 76000 Rouen, France.
Curcio H; Department of Pneumology, Centre Régionale de Lutte Contre le Cancer François Baclesse, 14000 Caen, France.
Ricordel C; Department of Pneumology, Centre Hospitalier Universitaire, 35000 Rennes, France.
Demontrond P; Department of Pneumology, Centre Régionale de Lutte Contre le Cancer François Baclesse, 14000 Caen, France.
Abdallahoui S; Department of Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France.
Baloglu S; Department of Radiological, Centre Hospitalier Universitaire de Strasbourg, 67200 Strasbourg, France.
Greillier L; Multidisciplinary Oncology and Therapeutic Innovations, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Aix Marseille University, 13015 Marseille, France.
Chouaid C; Department of Pneumology, Centre Hospitalier, 94000 Créteil, France.
Schott R; Department of Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Mar 21; Vol. 31 (3), pp. 1656-1666. Date of Electronic Publication: 2024 Mar 21.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Antineoplastic Agents, Immunological*/therapeutic use
Brain Neoplasms*
Antibodies, Monoclonal, Humanized*
Humans ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
Autorzy:
Sriphoosanaphan S; Department of Medicine, Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Pantumongkol W; Center for Value Driven Care, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Kulpeng W; Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Charonpongsuntorn C; Department of Internal Medicine, Medical Oncology Unit, Srinakharinwirot University, Nakhon Nayok, Thailand.
Tanwandee T; Division of Gastroenterology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Sukeepaisarnjaroen W; Department of Medicine, Gastroenterology Unit, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Sobhonslidsuk A; Department of Medicine, Division of Gastroenterology and Hepatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Tangkijvanich P; Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 21; Vol. 19 (3), pp. e0300327. Date of Electronic Publication: 2024 Mar 21 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Bevacizumab/therapeutic use ; Cost-Benefit Analysis ; Thailand ; Quality-Adjusted Life Years
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.
Autorzy:
Qiu L; Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
Ma L; Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
Xie Y; Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
Jin J; Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
Pan Y; Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
Li S; Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
Fan Z; Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China. .
Yu H; Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China. haiguo_.
Pokaż więcej
Źródło:
Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2024 Mar 19; Vol. 22 (1), pp. 38. Date of Electronic Publication: 2024 Mar 19.
Typ publikacji:
Journal Article
MeSH Terms:
Arthritis, Juvenile*/drug therapy
Antibodies, Monoclonal, Humanized*
Child ; Humans ; Male ; Female ; Antibodies, Monoclonal/adverse effects ; Retrospective Studies ; Adrenal Cortex Hormones/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
Autorzy:
Nakabori T; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Higashi S; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Abe Y; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Mukai K; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Ikawa T; Department of Radiation Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Konishi K; Department of Radiation Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Maeda N; Department of Diagnostic and Interventional Radiology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Nakanishi K; Department of Diagnostic and Interventional Radiology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Hasegawa S; Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Wada H; Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Ohkawa K; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Mar 15; Vol. 31 (3), pp. 1543-1555. Date of Electronic Publication: 2024 Mar 15.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*
Liver Neoplasms*
Antibodies, Monoclonal, Humanized*
Humans ; Bevacizumab ; Feasibility Studies ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.
Autorzy:
Liu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Ping L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Song Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Tang Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Zheng W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Liu W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Ying Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Zhang C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Wu M; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Feng F; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Lin N; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Tu M; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.
Xie Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2024 Mar 07; Vol. 22 (1), pp. 107. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Hodgkin Disease*/drug therapy
Hodgkin Disease*/etiology
Hodgkin Disease*/pathology
Hematopoietic Stem Cell Transplantation*
Antibodies, Monoclonal, Humanized*
Humans ; Gemcitabine ; Oxaliplatin/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Transplantation, Autologous ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.
Autorzy:
Chesdachai S; Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. .
Rivera CG; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Cole KC; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Teaford HR; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Gonzalez Suarez ML; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Larsen JJ; Department of Nursing, Mayo Clinic, Rochester, MN, USA.
Ganesh R; Department of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Tulledge-Scheitel S; Department of Community Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Razonable RR; Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 05; Vol. 14 (1), pp. 5430. Date of Electronic Publication: 2024 Mar 05.
Typ publikacji:
Journal Article
MeSH Terms:
Outpatients*
COVID-19*
Antibodies, Neutralizing*
Antibodies, Monoclonal, Humanized*
Adenosine Monophosphate/*analogs & derivatives
Alanine/*analogs & derivatives
Humans ; COVID-19 Vaccines ; SARS-CoV-2 ; COVID-19 Drug Treatment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
Autorzy:
Chen Q; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Sun Q; Guangzhou ZhongWei Public Health Technology Accessment Institute, Guangzhou, China.
Zhang J; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Li B; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Feng Q; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Liu J; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 04; Vol. 19 (3), pp. e0295090. Date of Electronic Publication: 2024 Mar 04 (Print Publication: 2024).
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Sorafenib/therapeutic use ; Cost-Effectiveness Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study.
Autorzy:
Lamas Pérez R; Headache Unit, Neurology Department, Virgen del Rocío University Hospital, Seville, Spain.
Millán-Vázquez M; Headache Unit, Neurology Department, Virgen del Rocío University Hospital, Seville, Spain.
González-Oria C; Headache Unit, Neurology Department, Virgen del Rocío University Hospital, Seville, Spain.
Pokaż więcej
Źródło:
Cephalalgia : an international journal of headache [Cephalalgia] 2024 Mar; Vol. 44 (3), pp. 3331024231226181.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Cluster Headache*/drug therapy
Cluster Headache*/chemically induced
Migraine Disorders*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Antibodies, Monoclonal/therapeutic use ; Prospective Studies ; Treatment Outcome ; Double-Blind Method
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
Autorzy:
Kinami T; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Uchikawa S; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kawaoka T; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Yamasaki S; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kosaka M; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Johira Y; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Yano S; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Amioka K; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Naruto K; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Yamaoka K; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Fujii Y; Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Fujino H; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Nakahara T; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Ono A; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Murakami E; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Okamoto W; Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Yamauchi M; Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Miki D; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Tsuge M; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Oka S; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Mar; Vol. 13 (5), pp. e7025.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*
Liver Neoplasms*
Hypertension, Portal*
Varicose Veins*
Antibodies, Monoclonal, Humanized*
Humans ; Bevacizumab
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study.
Autorzy:
Hershey AD; Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Paiva da Silva Lima G; Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA.
Pannacciulli N; Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA.
Mackowski M; Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA.
Koukakis R; Amgen Inc., Uxbridge, UK.
McVige JW; Dent Neurologic Institute, Amherst, New York, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2024 Mar; Vol. 17 (3), pp. e13755.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms:
Antibodies, Monoclonal, Humanized*/adverse effects
Migraine Disorders*/drug therapy
Adolescent ; Child ; Humans ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 11890

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies